Table 3 Prediction of optimal cytoreduction: computed tomography-based and clinically assessed parameters assigned a point value according to Bristow criteria (Approach A)
Specificity | NPV | PPV | Accuracy | Point | |
|---|---|---|---|---|---|
Radiographic | |||||
Peritoneal thickening, peritoneal implants >2 cm | 34.5 | 74.3 | 63.8 | 65.9 | 0 |
Bowel mesentery involvement | 75.4 | 61.8 | 73.6 | 67.5 | 2 |
Omental extension (spleen, stomach, lesser sac) | 92.9 | 50.4 | 82.8 | 56.2 | 1 |
Pelvic sidewall involvement and/or hydroureter | 80.2 | 45.6 | 59.5 | 48.7 | 0 |
Suprarenal aortic lymph nodes >1 cm | 86.0 | 47.7 | 70.0 | 52.3 | 0 |
Infrarenal aortic lymph nodes >2 cm | 94.2 | 48.5 | 82.1 | 53.3 | 0 |
Superficial liver metastases >2 cm and/or intraparenchimal liver metastases any size | 83.5 | 51.1 | 73.1 | 57.1 | 1 |
Large volume ascites (>500 ml) | 40.7 | 60.3 | 62.2 | 61.6 | 0 |
Diaphragmatic disease (widespread infiltrating carcinomasis, or confluent nodules) | 77.6 | 61.1 | 76.8 | 67.8 | 2 |
Clinical | |||||
Age, years (⩽65 vs >65) | 73.2 | 48.4 | 64.6 | 53.1 | 0 |
Ca125 levels, IU ml−1 (⩽500 vs >500) | 25.8 | 44.8 | 55.9 | 53.3 | 0 |
ECOG-PS (0–1 vs 2) | 91.9 | 54.1 | 85.7 | 62.0 | 2 |
